Abstract:For the immune system to function properly, the activation of leukocytes must be tightly regulated. Failures of immune control mechanisms underlie the aberrant targeting of self‐antigens (i.e. autoimmunity) and the collateral damage of healthy tissues during excessive responses to infectious threats or the unnecessary immune mobilization against innocuous commensal microbes. Foxp3‐expressing CD4+ Regulatory T cells (Tregs) are a major cellular force working to prevent these pathologies of immune dysregulation. These cells characteristically exhibit multiple suppressive function that is absolutely required for the maintenance of immune homeostasis. However, these cells can hamper desirable anti‐tumor immune responses in cancer patients. Accordingly, a relative abundance of Tregs in the tumor microenvironment (TME) is a negative prognostic factor in many cancers. Treg‐depleting or antagonizing strategies show promise as potential interventions capable of unleashing anti‐tumor immunity from suppression. The characteristic gene expression and suppressive function of Tregs depend considerably on the stable expression and activity of the transcription factor FOXP3. While transcriptional regulation of the Foxp3gene has been studied in depth, both the expression and function of this factor are also modulated at the protein level. However, the molecular players involved in posttranslational FOXP3 regulation are just beginning to be elucidated. We have found that in the absence of the E3 ligase TRAF6 Tregs were dysfunctional in vivo. In these studies, mice with Treg‐restricted deletion of TRAF6 were highly resistant to implanted tumors and displayed enhanced anti‐tumor immunity. We further determined that FOXP3 undergoes lysine‐63 linked (K63) ubiquitination at lysine 262, and this posttranslational modification was mediated by TRAF6. When deprived of TRAF6 activity or rendered insensitive to K63 ubiquitination, FOXP3 displayed aberrant, perinuclear accumulation and disrupted regulatory function. Thus, K63 ubiquitination by TRAF6 ensures proper localization of FOXP3 and facilitates the transcription factor's gene‐regulating activity in Tregs. These results implicate TRAF6 as a key, hitherto unappreciated posttranslational facilitator of FOXP3 stabilization and Treg suppressive function that may be targeted by novel tolerance‐breaking immunotherapies to improve anti‐tumor immunity and combat disease progression in cancer patients.This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity Via the Regulation of Ectonucleotidase Expression.

The Role of STAT3 in Antigen-Igg Inducing Regulatory CD4+Foxp3+T Cells

TCR Signaling Induces STAT3 Phosphorylation to Promote TH17 Cell Differentiation.

GATA3 induces the pathogenicity of Th17 cells via regulating GM-CSF expression

An Inhibitory Role for the Transcription Factor Stat3 in Controlling IL-4 and Bcl6 Expression in Follicular Helper T Cells.

Genome-wide Analysis of STAT3-Mediated Transcription During Early Human Th17 Cell Differentiation.

HIPK2 directs cell type–specific regulation of STAT3 transcriptional activity in Th17 cell differentiation

Transforming Growth Factor Β is Dispensable for the Molecular Orchestration of Th17 Cell Differentiation

Control of the Differentiation of Regulatory T Cells and TH17 Cells by the DNA-binding Inhibitor Id3

Egr2 is required for the activation of the TH17 pathogenetic program

The effects of post-translational modifications on Th17/Treg cell differentiation

The Transcription Factors Egr2 and Egr3 Are Essential for the Control of Inflammation and Antigen-Induced Proliferation of B and T Cells

A Requirement Of Stat3 Dna Binding Precludes Th-1 Immunostimulatory Gene Expression By Nf-Kappa B In Tumors

Gata3 plays a supportive role for the development of Tbet-expressing Th17 cells in EAE

The E3 Ligase TRAF6 Directs FOXP3 Localization and Facilitates Treg Function Through K63‐type Ubiquitination

Th17 cells inhibit CD8+ T cell migration by systematically downregulating CXCR3 expression via IL-17A/STAT3 in advanced-stage colorectal cancer patients

GITR Subverts Foxp3+ Tregs to Boost Th9 Immunity Through Regulation of Histone Acetylation

IL-4 and IL-13 Up-Regulate Intestinal Trefoil Factor Expression: Requirement for STAT6 and De Novo Protein Synthesis1

Transcription factor EGR2 controls homing and pathogenicity of TH17 cells in the central nervous system

TIF1γ regulates stability of T regulatory cells during inflammation

Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation